Systemic immunosuppressive agents were used by 85.7% and 78.5% of patients, respectively. Over time, patients with ANCA-positive vasculitis experienced 2.75-fold higher mortality than other patients with inflammatory eye disease. Ocular disease in patients with ANCA-positive vasculitis

Journal of Ocular Biology, Diseases, and Informatics

Volumn 3, Issue 1, 2010, Pages 12-19

  Watkins, Angela S ^a   Kempen, John H ^b,c,d   Choi, Dongseok ^a   Liesegang, Teresa L ^a   Pujari, S S ^e   Newcomb, Craig ^d   Nussenblatt, Robert B ^f   Rosenbaum, James T ^a,g   Thorne, Jennifer E ^h   Foster, C Stephen ^e,i   Jabs, Douglas A ^j,k   Levy Clarke, Grace A ^f,l   Suhler, Eric B ^a,m   Smith, Justine R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^f NATIONAL EYE INSTITUTE   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l Cataract and Laser Institute   (United States)

^m PORTLAND VA MEDICAL CENTER   (United States)

more..

Author keywords

ANCA positive vasculitis; Eye; Scleritis; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE DURATION; EPISCLERITIS; EYE DISEASE; EYE EXAMINATION; EYE INFLAMMATION; FEMALE; HUMAN; KERATITIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORBIT PSEUDOTUMOR; PRIORITY JOURNAL; SCLERITIS; UNITED STATES; UVEITIS;

EID: 78650195309     PISSN: None     EISSN: 19368445     Source Type: Journal    
DOI: 10.1007/s12177-009-9044-4     Document Type: Article

References (27)

1. Lefrak SS, Matteson EL. Freidrich Wegener: the past and present. Chest. 2007;132(6):2065.
2. Harman LE, Margo CE. Wegener's granulomatosis. Surv Oph-thalmol. 1998;42(5):458-80.
3. Sarraf P, Sneller MC. Pathogenesis of Wegener's granulomatosis: current concepts. Expert Rev Mol Med. 2005;7(8):1-19.
4. Cotch MF, Hoffman GS, Yerg DE, et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum. 1996;39(1):87-92.
5. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulo-matosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488-98.
6. Pakrou N, Selva D, Leibovitch I. Wegener's granulomatosis: ophthalmic manifestations and management. Semin Arthritis Rheum. 2006;35(5):284-92.
7. Robin JB, Schanzlin DJ, Meisler DM, et al. Ocular involvement in the respiratory vasculitides. Surv Ophthalmol. 1985;30(2):127-40.
8. Fechner FP, Faquin WC, Pilch BZ. Wegener's granulomatosis of the orbit: a clinicopathological study of 15 patients. Laryngoscope. 2002;112(11):1945-50.
9. Bhatia A, Yadava U, Goyal JL, Chaturvedi KU. Limited Wegener's granulomatosis of the orbit: a case study and review of literature. Eye. 2005;19(1):102-4.
10. Bambery P, Sakhuja V, Gupta A, et al. Wegener's granulomatosis in north India. An analysis of eleven patients. Rheumatol Int. 1987;7(6):243-7.
11. Sadiq SA, Jennings CR, Jones NS, Downes RN. Wegener's granulomatosis: the ocular manifestations revisited. Orbit. 2000;19(4):253-61.
12. Haynes BF, Fishman ML, Fauci AS, Wolff SM. The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature. Am J Med. 1977;63(1):131-41.
13. Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA. Ocular complications of Wegener's granulomatosis. Ophthalmology. 1983;90(3):279-90.
14. Charles SJ, Meyer PA, Watson PG. Diagnosis and management of systemic Wegener's granulomatosis presenting with anterior ocular inflammatory disease. Br J Ophthalmol. 1991;75(4):201-7.
15. Straatsma BR. Ocular manifestations of Wegener's granulomato-sis. Am J Ophthalmol. 1957;44(6):789-99.
16. Cutler WM, Blatt IM. The ocular manifestations of lethal midline granuloma (Wegener's granulomatosis). Am J Ophthalmol. 1956;42(1):21-35.
17. Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008;15(1):47-55.
18. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339: b2480.
19. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthal-mol. 1976;60(3):163-91.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
21. Harper SL, Letko E, Samson CM, et al. Wegener's granuloma-tosis: the relationship between ocular and systemic disease. J Rheumatol. 2001;28(5):1025-32.
22. White ES, Lynch JP. Pharmacological therapy for Wegener's granulomatosis. Drugs. 2006;66(9):1209-28.
23. Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46(7):1087-91.
24. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulo-matosis. N Engl J Med. 2005;352(4):351-61.
25. Perry SR, Rootman J, White VA. The clinical and pathologic constellation of Wegener granulomatosis of the orbit. Ophthalmology. 1997;104(4):683-94.
26. Woo TL, Francis IC, Wilcsek GA, et al. Australasian orbital and adnexal Wegener's granulomatosis. Ophthalmology. 2001;108(9):1535-43.
27. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990;33(8):1101-7.